KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should be a more personalized clinical intervention and coaching approach that better ensures lasting behavioral change. We’re looking to talk with stakeholders such as cardiologists, nurses, care management teams, and administrators to learn more about the unmet needs. This outreach is part of our participation in the Spring cohort of the Roanoke Acceleration and Mentoring Program (RAMP), so we would really appreciate any help. Please help us by filling in this brief, 10 question survey. Also, if you have some guidance or can connect us with someone in your network that fits the above roles please contact KinergyCare CEO Art Spivy at aspivy@kinergycare.com or (571) 277-5373. Thanks for your help!
News
Recent News
10/26/2026
ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies
ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …
10/26/2026
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …
10/23/2026
PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification
PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …